A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Act. Twice Daily
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Muscle Shoals, Alabama, United States
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Research Site
-
-
California
-
Anaheim, California, United States
- Research Site
-
Los Angeles, California, United States
- Research Site
-
Palmdale, California, United States
- Research Site
-
Rolling Hills Estates, California, United States
- Research Site
-
-
Colorado
-
Denver, Colorado, United States
- Research Site
-
Wheat Ridge, Colorado, United States
- Research Site
-
-
Connecticut
-
Stamford, Connecticut, United States
- Research Site
-
-
Delaware
-
Wilmington, Delaware, United States
- Research Site
-
-
Florida
-
Miami, Florida, United States
- Research Site
-
-
Indiana
-
Avon, Indiana, United States
- Research Site
-
-
Iowa
-
Iowa City, Iowa, United States
- Research Site
-
-
Kansas
-
Shawnee Mission, Kansas, United States
- Research Site
-
-
Louisiana
-
Mandeville, Louisiana, United States
- Research Site
-
-
Maryland
-
Wheaton, Maryland, United States
- Research Site
-
-
Michigan
-
Bay City, Michigan, United States
- Research Site
-
-
Missouri
-
Chesterfield, Missouri, United States
- Research Site
-
Kansas City, Missouri, United States
- Research Site
-
-
Nebraska
-
McCook, Nebraska, United States
- Research Site
-
Scottsbluff, Nebraska, United States
- Research Site
-
-
New Jersey
-
Brick, New Jersey, United States
- Research Site
-
Princeton, New Jersey, United States
- Research Site
-
-
New York
-
North Syracuse, New York, United States
- Research Site
-
-
North Dakota
-
Bismarck, North Dakota, United States
- Research Site
-
Fargo, North Dakota, United States
- Research Site
-
-
Ohio
-
Akron, Ohio, United States
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Research Site
-
-
Oregon
-
Bend, Oregon, United States
- Research Site
-
Lake Oswego, Oregon, United States
- Research Site
-
-
Pennsylvania
-
Bensalem, Pennsylvania, United States
- Research Site
-
Feasterville, Pennsylvania, United States
- Research Site
-
Pittsburgh, Pennsylvania, United States
- Research Site
-
-
Rhode Island
-
East Providence, Rhode Island, United States
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States
- Research Site
-
Gaffney, South Carolina, United States
- Research Site
-
Greer, South Carolina, United States
- Research Site
-
-
South Dakota
-
Rapid City, South Dakota, United States
- Research Site
-
Watertown, South Dakota, United States
- Research Site
-
-
Texas
-
Boerne, Texas, United States
- Research Site
-
Dallas, Texas, United States
- Research Site
-
El Paso, Texas, United States
- Research Site
-
San Antonio, Texas, United States
- Research Site
-
Waco, Texas, United States
- Research Site
-
-
Utah
-
Provo, Utah, United States
- Research Site
-
-
Washington
-
Spokane, Washington, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female, > 18 years of age
- Mild to moderate asthma requiring treatment with an inhaled corticosteroid
- Diagnosis of asthma for at least 6 months
Exclusion Criteria:
- Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
- Subjects with severe asthma, as judged by investigator
- Any significant disease or disorder that may jeopardize a subject's safety
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
To determine whether subjects respond similarly to the Onset of Effect Questionnaire items 2 and 5 when administered post-dose versus pre-dose and does that difference favour a bronchodilator treatment group over a non-bronchodilator treatment group
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
To determine if there is an association between the immediate physiological response to medication and the responses to OEQ items 2 and 5 and to determine what subjects mean when they say they feel their asthma maintenance medication 'working right away
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Tomas LG Andersson, MD, AstraZenenca
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Budesonide
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- D5896C00025
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.